18.2– tag –
-
Claudin18.2 ADC Development Part 1: Phase 1 Results and Clinical Significance of SHR-A1904
Antibody–drug conjugates (ADCs) targeting Claudin18.2 (CLDN18.2) have gained increasing attention as a novel therapeutic approach for advanced gastric and gastroesophageal junction (GEJ) cancers. Here, we summarize the phase 1 trial resu... -
Claudin18.2 ADC Development Part 0: Series Introduction
This series provides an in-depth review of the current landscape of Claudin18.2 (CLDN18.2)-targeted antibody–drug conjugates (ADCs) in gastric and gastroesophageal junction (GEJ) cancers. Structured into five parts, it covers pivotal cli...
1